Mouse COVID 19 Spike Coronavirus Monoclonal Antibody | anti-COVID-19 antibody

SARS-CoV/SARS-CoV-2 Spike antibody, Chimeric MAb

• Applications: ELISA, Neutralization Assay, Flow Cytometry, Functional Assay, Immunocytochemistry, Immunofluorescence
• Purity: Protein A
• Synonyms: COVID 19 Spike Coronavirus; Monoclonal Antibody; SARS-CoV/SARS-CoV-2 Spike antibody; Chimeric MAb; 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike; anti-COVID-19 antibody

• Host: Mouse
• Clonality: Monoclonal
• Isotype: Human (kappa / IgG1 constant) chimeric antibody
• Clone Number: D001
• Specificity: SARS Coronavirus spike. Has cross-reactivity in ELISA with:; SARS-CoV Spike S1 Protein (Cat# MBS8122160); SARS-CoV-2 (2019-nCoV) Spike S1 Protein; SARS-CoV-2 (2019-nCoV) Spike RBD Protein (Cat# MBS8118817); No cross-reactivity in ELISA with: ; MERS-CoV Spike S1 Protein; HCoV-HKU1 (isolate N1) Spike S1 Protein; HCoV-HKU1 (isolate N5) Spike S1 Protein (Cat# MBS8122435); HCoV-NL63 Spike S1 Protein; HCoV-229E Spike S1 Protein (Cat# MBS8122434); HCoV-OC43 Spike S1+S2 ECD Protein (Cat# MBS8122438)
• Purity/Purification: Protein A
• Form/Format: Liquid. 0.2 um filtered solution in PBS

• Applicable Applications for anti-COVID-19 antibody: ELISA (EIA), Neutralization, Flow Cytometry (FC/FACS), Immunocytochemistry (ICC), Immunofluorescence (IF)
• Application Notes: ELISA: 1:5000-1:10000; ICC-IF: 1:20-1:100; FCM: 1:25-1:100
• Immunogen: Recombinant SARS-CoV Spike RBD Protein (Catalog#MBS8122161)
• Preparation: It is a chimeric monoclonal antibody combining the constant domains of the human IgG1 molecule with mouse variable regions. The variable region was obtained from a mouse immunized with purified, recombinant SARS-CoV Spike RBD Protein. The antibody was produced using recombinant antibody technology.
• Microneutralizaiton (MN): The neutralization activity is Measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 (2019-nCoV) Spike Pseudovirus under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# MBS8123645). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. The IC50 is typically 0.646 ug/mL.
• Preparation and Storage: This antibody can be stored at 2-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20? to -80 degree C. Preservative-Free. Avoid repeated freeze-thaw cycles.

Testing Data

(Serial dilutions of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# MBS8123645) was detected by SARS-CoV-2 (2019-nCoV) Inhibitor Screening ELISA Kit. The IC50 is typically 0.5-5 nM.)

Testing Data

(The neutralization activity is Measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 (2019-nCoV) Spike Pseudovirus under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# MBS8123645). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. The IC50 is typically 0.646 µg/mL.)

Flow Cytometry (FC/FACS

(Flow cytometric analysis of SARS-COV-2 Spike overexpressed HEK293 Cells were stained with purified anti-SARS-COV-2 Spike Chimeric MAb, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.)

Immunofluorescence (IF)

(Immunofluorescence analysis of SARS-COV-2 Spike overexpressed HEK293 Cells were stained with purified anti-SARS Spike Chimera Mab,then a FITC-conjugated second step antibody.)

Related Product Information for anti-COVID-19 antibody

The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.

References

Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.